GSK's ViiV, under threat from Gilead-Merck collab, eyes 'ultra-long-acting' HIV drugs with Halozyme deal

GSK’s HIV-focused ViiV Healthcare is paying Halozyme Therapeutics $40 million upfront to gain exclusive rights to the latter’s Enhanze drug delivery technology for use against four HIV targets, the two companies said Tuesday. Up to $175 million in milestones and mid-single-digit royalties on future sales are up for grabs.